SL
BMRN icon

Sentinus LLC’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sentinus LLC’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$301K Sell
5,260
-3,223
-38% -$177K 0.02% 482
2026
Q1 		$479K Buy
8,483
+1,783
+27% +$104K 0.04% 303
2025
Q4 		$398K Buy
+6,700
New +$365K 0.04% 360

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Sentinus LLC's BMRN Position: Q2 2026 in Review

Sentinus LLC reduced its BioMarin Pharmaceuticals (BMRN) stake by 38% in Q2 2026, selling an estimated $177K and leaving 5,260 shares worth $301K. The position accounts for 0.02% of the portfolio, ranked #482.

Sentinus LLC first reported a position in BMRN in Q4 2025 and has held it in 3 quarters since. The position peaked at $479K in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Sentinus LLC held 5,260 shares of BioMarin Pharmaceuticals worth $301K as of Q2 2026.
  • Sentinus LLC sold 3,223 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $177K.
  • BioMarin Pharmaceuticals made up 0.02% of Sentinus LLC's portfolio in Q2 2026, its #482 holding.
  • Sentinus LLC first reported a position in BioMarin Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Sentinus LLC's BioMarin Pharmaceuticals position peaked at $479K in Q1 2026.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Sentinus LLC's 13F filing for Q2 2026, filed 11 Aug 2026.